Posts Tagged "NPS"

Identifcation and characterization of the new opioid derivative 3,4-dichloro-N-(2-(diethylamino)cyclohexyl)-N-methylbenzamide (U-49900)

Posted on Nov 17, 2017 in News

Identifcation and characterization of the new opioid derivative 3,4-dichloro-N-(2-(diethylamino)cyclohexyl)-N-methylbenzamide (U-49900)

This article focuses on the repercussions of scheduling NPS as they emerge on the “legal” market. Particularly U-49900, a synthetic opioid that is an analogue of U-47700 (which is itself an analog of an earlier now-banned opioid: AH-7921) It seems that demand for novel opioids does not decrease when a compound is scheduled, and if the supply for a certain substance dwindles, users are bound to seek an alternative. While it is clear that a solution needs to be found, this article suggests that perhaps quickly and systematically scheduling new compounds as they gain popularity can...

Read More

Identification and characterization of a putative new psychoactive substance, 2-(2-(4-chlorophenyl)acetamido)-3-methylbutanamide, in Spain

Posted on Nov 6, 2017 in News

Identification and characterization of a putative new psychoactive substance, 2-(2-(4-chlorophenyl)acetamido)-3-methylbutanamide, in Spain

This article describes the identification and characterization of 2-(2-(4-chlorophenyl)acetamido)-3-methylbutanamide, a putative new psychoactive substance, through GC/MS, LC/MS, NMR, FTIR, UV, Single-crystal X-ray diffraction, and NMR.  ...

Read More

Something new about something old: a 10-year follow-up on classical and new psychoactive Tryptamines and results of analysis

Posted on Nov 2, 2017 in News

Something new about something old: a 10-year follow-up on classical and new psychoactive Tryptamines and results of analysis

This article explores the presence of tryptamines classified as NPS among the substances delivered for analysis to a harm-reduction organization, to describe the substances found in the samples after analysis, and to compare analytical results of regulated vs. non-regulated tryptamines. It argues that there is a need for further research in order to prevent the potential health risks associated with their use....

Read More

Patterns of use and toxicity of new para-halogenated substituted cathinones: 4-CMC (clephedrone), 4-CEC (4-chloroethcatinone) and 4-BMC (brephedrone)

Posted on Oct 30, 2017 in News

Patterns of use and toxicity of new para-halogenated substituted cathinones: 4-CMC (clephedrone), 4-CEC (4-chloroethcatinone) and 4-BMC (brephedrone)

This article presents results of the analysis of 3 NPS: clephedrone (4-CMC), 4-chloroethcathinone (4-CEC), and brephedrone (4-BMC) on recreational drug markets and a systematic review of all the available information concerning these substances. It presents the possibility that the emergence of these substances is the next step in the cat-and-mouse game existing between drug producers and legislation....

Read More

Our International Drug Testing Service detects a dangerous mixture from Australia

Posted on Feb 4, 2017 in News

After several deaths, poisonings and severe intoxications in several Melbourne (Australia) clubs in 15-17 January, we have received a sample of capsules sold as MDMA from Australia, related to these health problems. The complete drug testing has revealed the composition of the sample: 4-FA (4-fluoroamphetamine): a psychoactive research chemical of the phenethylamine and substituted amphetamine chemical classes. 25C-NBOMe: a psychedelic drug and derivative of the psychedelic phenethylamine 2C-C. We have not been able to quantify the amount of this substance MDMA...

Read More

Pin It on Pinterest